Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis

Rheumatology

Volumn 44, Issue 12, 2005, Pages 1503-1506

  Bezerra, M C ^a   Calomeni, G D ^a   Caparbo, V F ^a   Gebrim, E S ^a   Rocha, M S ^a   Pereira, Rosa Maria Rodrigues ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arterial calcification; Bone mineral density; sRANKL; Takayasu arteritis

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

AORTA ARCH SYNDROME; ARTERY CALCIFICATION; ARTICLE; ATHEROGENESIS; BLOOD VESSEL CALCIFICATION; BONE DENSITOMETRY; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RISK FACTOR; VASCULAR DISEASE;

ADULT; AORTIC DISEASES; BONE DENSITY; BONE DISEASES, METABOLIC; CALCINOSIS; CARRIER PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; LUMBAR VERTEBRAE; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; PREMENOPAUSE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TAKAYASU'S ARTERITIS;

EID: 28544444640     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei045     Document Type: Article

References (20)

1. Blank M, Krause I, Goldkorn T et al. Monoclonal anti-endothelial cell antibodies from a patient with Takayasu arteritis activate endothelial cells from large vessels. Arthritis Rheum 1999;42:1421-32.
2. Yamato M, Lecky JW, Hiramatsu K, Kohda E. Takayasu arteritis: radiographic and angiographic findings in 59 patients. Radiology 1986;161:329-34.
3. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC. Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study. Arterioscler Thromb Vasc Biol 2000;20:1926-31.
4. Ramsey-Goldman R, Manzi S. Association of osteoporosis and cardiovascular disease in women with systemic lupus erythematosus. Arthritis Rheum 2001;44:2338-41.
5. McFarlane SL, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease. Brittle bones and boned arteries, is there a link? Endocrine 2004;23:1-10.
6. Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 2004;286:686-96.
7. Bezerra MC, Carvalho JF, Prokopowitsch AS, Pereira RMR. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 2005;38:161-70.
8. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.
9. Pennisi P, Signorelli SS, Riccobene S et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporosis Int 2004;15:389-95.
10. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89: 4246-53.
11. Banks LM, Lees B, MacSweeney JE, Stevenson JC. Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: Links between osteoporosis and cardiovascular disease? Eur J Clin Invest 1994;24:813-17.
12. Barengolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C, Chomka EV. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 1998;62: 209-13.
13. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95: 1046-57.
14. Hofbauer LC, Schoppet M. Clinical implications of osteoprotegerin/RANKL/ RANK system for bone and vascular diseases. J Am Med Assoc 2001;202:490-5.
15. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
16. Moon J, Bandy B, Davison AJ. Hypothesis: Etiology of atherosclerosis and osteoporosis. Are imbalances in the calciferol endocrine system implicated? J Am Coll Nutr 1992;1:567-83.
17. Yamaguchi T, Sugimoto T, Yano S et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J 2002;49:211-17.
18. Schoppet M, Schaefer JR, Hofbauer LC. Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 2003;107:76.
19. Dhore C, Cleutjens J, Lutgens E et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003.
20. Sattler A, Schoppet M, Schaefer J, Hofbauer L. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tis Int 2004;74:103-6.